Myriad’s myRisk Hereditary Cancer test finds inherited gene mutations in more than 12
 

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk Hereditary Cancer test will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif.

More...